Skip to main content
. 2017 Aug 29;2017(8):CD004064. doi: 10.1002/14651858.CD004064.pub4

Comparison 3. 5‐FU/cisplatin/anthracycline combinations versus 5‐FU/cisplatin combinations (without anthracyclines).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Overall survival 4 579 Hazard ratio (Fixed, 95% CI) 0.74 [0.61, 0.89]
2 Tumour response 1   Odds Ratio (M‐H, Fixed, 95% CI) Subtotals only
3 Time to progression 1   Hazard Ratio (Fixed, 95% CI) Subtotals only